CareDx Inc. (CDNA)
Summary
CDNA Chart
People also search for
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 131 | $2,982.24 | $3,830.44 | $848.2 | 28.44% |
| BG Bart Gancher Intech Investment Management LLC | 15,224 | $286,911.94 | $444,236.32 | $157,324.38 | 54.83% |
 Melissa Tiscareno Bradley & Co. Private Wealth Management LLC | 8,087 | $550,643.83 | $234,916.03 | -$315,727.8 | -57.34% |
 Joseph Castro Nuveen LLC | 390,294 | $7.09M | $11.36M | $4.28M | 60.38% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 21,242 | $378,032.36 | $629,595.89 | $251,563.53 | 66.55% |
CareDx Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 53.86 | $1,154.73 | $1,602.3 | $447.57 | 38.76% |
CareDx Inc. (CDNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CareDx Inc. ever had a stock split?
CareDx Inc. Profile
| Professional Services Industry | Industrials Sector | John Walter Hanna Jr. CEO | NASDAQ (NMS) Exchange | 14167L103 CUSIP |
| US Country | 644 Employees | - Last Dividend | - Last Split | 17 Jul 2014 IPO Date |
Overview
CareDx, Inc. is a pioneering company focused on the discovery, development, and commercialization of diagnostic solutions targeted at transplant patients and their caregivers, both within the United States and internationally. The company has established a strong presence in the market through its comprehensive portfolio of products designed to enhance the care and management of transplant recipients. Its offerings span across various transplant types, including kidney, heart, and lung transplants. Initially founded as XDx, Inc., the company underwent a rebranding to CareDx, Inc. in March 2014, marking a significant milestone in its evolution. Since its incorporation in 1998, CareDx, Inc. has been headquartered in South San Francisco, California, where it continues to push the boundaries of transplant diagnostics and patient care.
Products and Services
- AlloSure Kidney - This innovative donor-derived cell-free DNA (dd-cfDNA) solution is designed specifically for kidney transplant patients, aiming to provide critical insights into the health and viability of the transplanted organ.
- AlloMap Heart - A gene expression solution that serves heart transplant patients, AlloMap Heart aids in the non-invasive monitoring of the immune system’s response to the transplanted heart, offering valuable information for patient management.
- AlloSure Heart - Similar to its kidney-focused counterpart, AlloSure Heart is a dd-cfDNA solution tailored for heart transplant recipients, providing essential data on graft health.
- AlloSure Lung - This specialized dd-cfDNA solution is crafted for lung transplant patients, enabling precise monitoring of the transplanted lung’s condition.
- Olerup SSP - Utilizing sequence specific primer technology, Olerup SSP offers a method for typing human leukocyte antigen (HLA) alleles, a critical factor in transplant compatibility and success.
- QTYPE - Designed for precision in HLA typing, QTYPE enhances the accuracy of transplant compatibility assessments, facilitating improved outcomes.
- Ottr - A comprehensive transplant patient management software, Ottr streamlines the process of monitoring and managing transplant recipients’ care.
- AlloSeq Tx - Providing high-resolution HLA typing, AlloSeq Tx delivers enhanced precision in assessing compatibility between donors and recipients.
- AlloSeq cfDNA - A surveillance solution measuring dd-cfDNA in blood, AlloSeq cfDNA offers a non-invasive means to monitor transplant health.
- AlloSeq HCT - Targeted at stem cell transplant recipients, AlloSeq HCT is a chimerism testing solution that evaluates the level of integration of transplanted cells.
- Allocell - This surveillance solution monitors the engraftment and persistence of allogeneic cells in patients who have undergone cell therapy transplants, supporting long-term transplant success.
- XynQAPI - A cloud-based transplant quality management software, XynQAPI aids healthcare providers in tracking and improving transplant outcomes through data analytics and insights.
- AlloCare - A mobile app offering a patient-centric resource for transplant recipients, AlloCare provides tools and information to support post-transplant life and health.
Additionally, CareDx has fostered strategic partnerships, including a license agreement with Illumina, Inc. for the development and commercialization of next-generation sequencing (NGS) products and technologies, and with Cibiltech SAS for the commercialization of iBox software, which provides predictive analysis of post-transplantation kidney allograft loss.
